Elorali and Orforgli Are the Next Molecules in the Weight Loss Pipeline

*This article is community-sourced educational material, not medical advice. The compounds tracked here as elorali and orforgli are eloralintide and orforglipron, investigational molecules with unfinished programs, and everything below describes what the research-peptide community reports and what the trials have shown so far. Research use only.*

The pipeline behind retatrutide is moving, and the community that runs reta today already watches it with the same numbered skepticism it applies to the trials themselves. Eloralintide, the selective amylin agonist the community calls elora, and orforglipron, the oral GLP-1 that works as a daily pill, are the two names that keep coming up, with cagrilintide sitting between them as the amylin-class molecule people can buy today. This article maps what the community knows about each, why the pipeline matters for current reta users, and what remains unknown.

I · The pipeline behind retatrutide is already crowded

The common picture of the GLP-1 market ends at retatrutide, as if the strongest triple agonist were the finish line, and the discourse in the research subreddits shows a different shape, because the next molecules already carry phase 2 readouts, registered trials, and kit pricing that people compare in public threads.¹ A knowledgeable amateur who functions as the community’s trial-watcher keeps a running pipeline watchlist, and as of mid-2026 it reads eloralintide at an average of 20.1% weight loss at 48 weeks on its phase 2 max-dose arm, cagrilintide at 11.8% over 68 weeks, orforglipron ahead of Rybelsus on HbA1c in a head-to-head, plus 25mg tirzepatide in trials, the 7.2mg Wegovy dose, VK2735 in both subcutaneous and oral forms, and brenipatide, a neuro GLP-1 under study for alcohol, cigarette, and bipolar indications.² The same discourse reports that retatrutide itself is being trialed at higher doses in the 20-25mg range, which means the current molecule may not even be the ceiling of its own program.³

That watchlist matters for current reta users because it defines the decision space they will face: whether to add an amylin compound at a plateau, whether an oral GLP-1 belongs in a maintenance plan, and whether the retatrutide dose ladder has room to grow. The corpus is community discourse by a knowledgeable amateur rather than expert teaching, so none of this is clinical guidance, and the useful part is the labeling discipline the community models, since it marks what it knows, what it heard, and what it is still waiting on.⁴

Building that watchlist is a literacy skill, since the crowd reads trial registries and phase 2 readouts alongside gray-market vendor pages as one continuous signal, and checking one source against another keeps the pipeline talk honest. The same account that runs the list corrects misread studies in public threads and debunks AI-generated pharmacokinetic models, treating any number with no paper behind it as noise until proven otherwise.²

The pipeline is moving on the same calendar as current protocols, so the practical question for someone on reta today is how to position a plan that may outlive the current molecule. The community’s answer so far is structural: reta stays the engine, the amylin class is the add-on candidate, and the oral GLP-1 is a separate question entirely, which is why each one gets its own section here.

II · Eloralintide, the amylin molecule the community calls super-cagri

The amylin system is the quiet third rail of the weight-loss pipeline, because the first widely available amylin-class drug, cagrilintide, works but frustrates many of the people who try it, and eloralintide is the molecule the community believes finally gets the selectivity right. The shorthand the trial-watcher uses is precise: “Think of it as super-cagri. What tirz is to sema, elora is to cagri.” [anecdotal] ⁵ The mechanism difference is receptor selectivity, since cagrilintide is a dual amylin-calcitonin receptor agonist while eloralintide is selective for the AMY1 receptor with little calcitonin receptor effect, and the community reads that as a gentler side effect profile with a cleaner metabolic signal.⁶ The design choice itself earns credit in the discourse, which treats the bet on a selective AMY1 agonist as the move that separates the molecule from the broader dual-receptor approach taken elsewhere in the field.⁷

The selectivity distinction matters mechanistically, because amylin is the appetite pathway the GLP-1s leave mostly untouched, and a receptor profile that hits amylin without dragging in the calcitonin receptor should in theory deliver the appetite signal with fewer of the metabolic side effects that show up on the dual receptor drug. The community watches the distinction closely because the amylin add-on exists to restore appetite control on top of a GLP-1 that has done its weight work, and a cleaner profile is what makes it tolerable at the doses that matter.⁶

On the numbers side, the community’s tracked phase 2 readout for eloralintide sits at “average weight loss at 48 weeks on the phase 2 trial max dose was 20.1%”, which the same account describes as comparable to tirzepatide and ahead of every non-GLP alternative.⁸ Two trial signals point forward: Enlighten-6, which studies adding eloralintide to weight-stable GLP-1 patients, and a phase 1 combination with tirzepatide whose data the community reports as released.⁹ The gray market has already responded, with eloralintide raws circulating before finished product, group-buy pricing around $320 for a 10mg kit, and a community warning that the compound is “more challenging to manufacture and test than any of the other peptides”.¹⁰

The reason current reta users should care is the plateau problem, since the community’s protocol doctrine treats eloralintide as the add-on candidate for people who have pushed reta to a dose that works and stopped losing, and the Enlighten-6 design speaks directly to that population because it studies exactly the scenario of adding elora on top of a weight-stable GLP-1.¹¹ What stays unknown is the dose, the timing, and the real-world side effect profile, because phase 3 data has to arrive before the community will treat any of those as settled.

III · Cagrilintide, the bridge molecule available today

The community’s view of cagrilintide reads as a running critique that still ends in a recommendation, since the same people who call it crude are the ones who tell plateaued reta users to add it, and that tension is the honest picture of the molecule. The trial-watcher’s summary of it runs:

“It’s a dual amylin-calcitonin receptor agonist with an average weight loss of 11.8% over 68 weeks. Substantially weaker than eloralintide with a harsher side effect profile and inferior metabolic improvement, but it’s available today and should be quite a bit cheaper for awhile.”

Community report, r/GLP1ResearchTalk discourse, 2026

The availability point matters because a molecule on the gray market today gives reta users a live test of whether the amylin pathway fixes the appetite gap at a price that makes sense. The community’s economics frame cagrilintide as the cheaper option relative to what is coming, and a 68-week horizon measures the effect on the maintenance timeline that matters for people who plan to stay on the drug.

The practical guidance that follows from that critique is consistent across the corpus: cagrilintide is the only meaningful add-on for appetite non-response once reta is at a working dose, with the instruction to “toss cagri on top” [anecdotal] ¹² if appetite suppression is the missing piece, and the dosing caveat that it makes sense only at or near the max reta dose. The side effects are the reason for the caution, because the community repeatedly flags fatigue, calling the compound “kind of notorious for causing fatigue” [anecdotal] ¹³ and rating it weaker than semaglutide, tirzepatide, or retatrutide alone, with one account going further and calling cagri “kind of ass” as far as drugs go while still conceding its place in the stack.

The sharper criticism in the corpus is that cagrilintide is a “poorly designed drug” [anecdotal] whose calcitonin agonism and insulin suppression are the price of its dual receptor profile, and the same comment ranks the combinations in order, holding that “Reta/elora > reta/cagri. And in most cases reta > reta/cagri.” [anecdotal] ¹⁴ That ranking is community opinion, but it encodes a real lesson for the amylin class, which is that the pathway earns its place on top of a working GLP-1 only when the add-on is clean enough to add benefit without adding noise.

IV · Orforglipron, the oral GLP-1 that skips the needle

Orforglipron answers a question the injected peptides did not have to face, which is whether a daily oral molecule can carry real GLP-1 efficacy, and the community’s answer starts with chemistry, since orforglipron is a small molecule, room-temperature stable, and as one comment puts it, “which isn’t a peptide” [anecdotal] ¹⁵. The efficacy anchor the community cites is the head-to-head against oral semaglutide published in the Lancet, quoted byte-exact:

“Full dose orforglipron (36mg) reduced HbA1c by 1.91% vs full dose Rybelsus (14mg) at 1.47%. Even low dose orforglipron (12mg) beat Rybelsus with an HbA1c reduction of 1.71%.”

Community report, r/GLP1ResearchTalk discourse, 2026

The weight-loss picture is more modest, since the community describes orforglipron at roughly half of retatrutide’s weight loss, and the gray market’s early verdict on the compound is underwhelming, with the community noting that the SNAC-based oral semaglutide did not make it to the gray market and that orfo’s arrival has been quieter than the hype suggested.¹⁶ The most useful caution in the corpus is the switch-trial finding, which the account flags as hedged because it mixes mice with hints in humans: people switching from semaglutide to orforglipron maintained their weight, while people switching from tirzepatide regained “a substantial amount of weight”, settling at “a long-term maintenance weight as if they’d only ever used the weaker drug”. [anecdotal] ¹⁷

The delivery difference changes the economics of the whole category, because a room-temperature-stable small molecule removes the cold chain and the reconstitution ritual, and its manufacturing cost sits far below anything a peptide synthesis line can reach, which is why the community reads orforglipron as the first real cost disruption in the GLP-1 aisle. The flip side is the adherence question that weekly injections quietly solved, since a pill asks for daily discipline from people who have built a once-a-week routine over months, and the gray market’s lukewarm early response suggests uptake may lag the chemistry.¹⁶

The market framing is where the community gets blunt, with the trial-watcher’s opinion on what a cheap oral that works does to the incumbent: “An oral drug that’s cheap as heck to make and as effective as Wegovy? They’re toast.” [anecdotal] ¹⁸ What remains unknown about orforglipron is substantial: real-world adherence to a daily pill versus a weekly injection, whether oral efficacy holds at maintenance, and how the approval timeline plays out, since community reports on the approval status shifted across the corpus window, with some threads treating it as done and others as imminent.¹⁹

V · Why the pipeline matters for current reta users

The through-line of the entire corpus is that reta is the engine, and the community’s repeated line on stacking is that “reta did about 99% of the work”, with the longer version warning that anyone running reta alongside a giant stack of other peptides will find reta doing nearly all of the work anyway.²⁰ The same account distills what works down to four things: a GLP-1 with amylin added when needed, resistance training, protein, and testosterone when it makes sense for the individual.²¹ The pipeline compounds slot into that framework as options, with cagrilintide available now for appetite non-response, eloralintide as the cleaner future add-on for plateaus, and the oral GLP-1 as a maintenance-adjacent question rather than a replacement for the engine.

The protocol doctrine around the engine itself does not change with the pipeline: dosing follows the phase 3 ladder, switching from high-dose tirzepatide is the failure mode the community warns about most, maintenance is a chronic medication question, and the dose that keeps weight stable is the maintenance dose regardless of which molecule carries it.²² The pipeline adds options to that framework, and the community’s practical stance is to keep the engine running, add the amylin only when the appetite signal is the bottleneck, and let the phase 3 data do the talking on everything else.

The maintenance doctrine deserves its own emphasis because it is where the pipeline intersects the longest: the community treats these drugs as chronic therapy and compares stopping them to stopping blood pressure medication, with most people who stop expected to regain the weight, which makes the add-on question a decade-long planning question.²² The same logic governs switching, since the corpus’s most repeated warning is that moving from a high tirzepatide dose to a low retatrutide dose feels like injecting water, and the pipeline version of that lesson is that any move between molecules needs a dose-matched bridge.

VI · What the community still does not know

The honest summary of the pipeline is a list of open questions, and the first one is eloralintide’s phase 3 record, since the 20.1% figure comes from a phase 2 arm with no completed phase 3 efficacy data behind it.²³ The second is equivalence: the community trades rough dose comparisons between the new molecules and the current drugs as conversational shorthand, and none of that arithmetic is established trial data, so it has no place in a protocol decision. The third is timing, because the corpus deliberately avoids promising readout dates or approval windows, and anyone citing a specific month for phase 3 results is working ahead of the record.

The misinformation problem is real enough that the community has made fact-checking part of its identity, with the recurring warning that “Lots of fake AI generated information in this space. It’s important to use quality sources of information.” [anecdotal] ²⁴ The most documented case is the influencer Trevor Bachmeyer, whose claims that reta requires carbs were traced by the community to fabricated ChatGPT citations, and the community’s response to the AI-slop consumer is to dismantle the claims with actual citations from the trial PDFs.²⁵ That is the pipeline lesson that transfers to the new molecules: check who is citing what, read the source paper, and treat any number that arrives without a named study as a claim to verify.

The verification practice that holds the pipeline together is mundane and worth spelling out: the community checks vendor claims against independent testing and influencer claims against the trial PDFs, then reads trial summaries against the numbers in the paper, and each habit transfers directly to elorali and orforgli content. A figure with a named paper and a readable number counts as evidence, and a figure from a screenshot counts as a rumor, a workable standard for molecules without a finished record.

The closing stance is the standing one for this site: this article is community-sourced, not medical advice, and everything here is research information for people who are already deep in the peptide space. Eloralintide and orforglipron are investigational molecules with real promise and real unknowns, the community’s knowledge of them is a running commentary rather than a settled record, and the right use of this material is understanding the pipeline, then letting the trials decide.